A phase 2 study of cisplatin in patients with hepatocellular carcinoma.

摘要: A phase 2 study of cisplatin was performed in 28 previously untreated patients with unresectable hepatocellular carcinoma. The drug given intravenously at a dose 80 mg/m2/day every 4 weeks. Of 26 evaluated, (15.4%) showed partial responses lasting for > 3 months, while no patient achieved complete response. 22 whose serum level alpha-fetoprotein (AFP) high (> 400 ng/ml) before treatment, 6 (27.3%) 50% reduction AFP levels after treatment. current indicates that is an anticancer agent worthy further testing this disease.